20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC

Impact · against what's priced in

The news is immaterial for Bristol Myers Squibb. The reported earnings beats and guidance are already reflected in analyst consensus and price targets, while the institutional buying involves positions that are negligible relative to the company's $120.89 billion market capitalization.

BMY+0.00

No priced-in read yet

In context

The purchase of 20,370 shares by Apella Capital LLC is immaterial to a $120.89 billion market cap, and the reported Q3 EPS beat of $2.04 against $1.60 is already reflected in current analyst ratings and price targets.

Read from the article alone

• earnings
• healthcare
• BMY
• analyst ratings
• biopharmaceuticals
• insider trading
• institutional ownership
• price targets
• sec filings

Search tags